Literature DB >> 26743897

(68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma.

Arun Sasikumar1, Ajith Joy2, Raviteja Nanabala2, M R A Pillai2, Boben Thomas3, K R Vikraman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26743897     DOI： 10.1007/s00259-015-3297-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  ⁶⁸Ga-PSMA imaging of metastatic breast cancer.

Authors:  Mike Sathekge; Moshe Modiselle; Mariza Vorster; Neo Mokgoro; Nozipho Nyakale; Brenda Mokaleng; Thomas Ebenhan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-01       Impact factor: 9.236

2.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

3.  Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Authors:  Samuel R Denmeade; Annastasiah M Mhaka; D Marc Rosen; W Nathaniel Brennen; Susan Dalrymple; Ingrid Dach; Claus Olesen; Bora Gurel; Angelo M Demarzo; George Wilding; Michael A Carducci; Craig A Dionne; Jesper V Møller; Poul Nissen; S Brøgger Christensen; John T Isaacs
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

4.  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

5.  Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Authors:  Natsuko Nomura; Sandra Pastorino; Pengfei Jiang; Gage Lambert; John R Crawford; Marco Gymnopoulos; David Piccioni; Tiffany Juarez; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  Cancer Cell Int       Date:  2014-03-20       Impact factor: 5.722
  5 in total
  30 in total

1.  68Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma.

Authors:  Rita Chahinian; Ahmad El-Amine; Sayed Matar; Mostafa Annan; Ali Shamseddine; Mohamad Haidar
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

2.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 3.  HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT).

Authors:  İsa Burak Güney
Journal:  J Gastrointest Cancer       Date:  2017-09

4.  The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Authors:  Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

5.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

6.  Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy.

Authors:  Jolanta Kunikowska; Królicki Bartosz; Królicki Leszek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-31       Impact factor: 9.236

7.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

8.  Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma.

Authors:  Scott P Campbell; Alexander S Baras; Mark W Ball; Max Kates; Noah M Hahn; Trinity J Bivalacqua; Michael H Johnson; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Ann Nucl Med       Date:  2017-10-24       Impact factor: 2.668

9.  Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.

Authors:  Venkata Subramanian Krishnaraju; Rajender Kumar; Bhagwant Rai Mittal; Vishal Sharma; Harjeet Singh; Ritambhra Nada; Amanjit Bal; Manish Rohilla; Harmandeep Singh; Surinder S Rana
Journal:  Eur Radiol       Date:  2020-10-01       Impact factor: 5.315

Review 10.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.